Everest Medicines Limited (HKG:1952)
Hong Kong · Delayed Price · Currency is HKD 35.50
+1.70 (5.03%)
Oct 21, 2026, 1:45 PM HKT
Everest Medicines Market Cap
Everest Medicines has a market cap or net worth of 12.48 billion as of October 20, 2026. It is the 7,740th most valuable company in the world and the 398th biggest in Hong Kong. Its market cap has decreased by 30.79% in one year.
Market Cap
12.48B
Enterprise Value
12.43B
Revenue
2.78B
Global Rank
Country Rank
#398 Hong Kong
PE Ratio
n/a
ChartMarket Cap Chart
Since October 9, 2020, Everest Medicines's market cap has decreased from 20.64B to 12.48B, a decrease of -39.52%. That is a compound annual growth rate of -8.00%.
| Date | Market Cap | % Change |
|---|---|---|
| Oct 21, 2026 | 12.48B | -4.47% |
| Dec 31, 2025 | 13.06B | -16.21% |
| Dec 31, 2024 | 15.59B | 132.87% |
| Dec 29, 2023 | 6.70B | 24.60% |
| Dec 30, 2022 | 5.37B | -47.96% |
| Dec 31, 2021 | 10.33B | -47.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Oct 9, 2020 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Related Stocks
| Company | Market Cap |
|---|---|
| Duality Biotherapeutics | 15.39B |
| Metis TechBio | 14.10B |
| Ascentage Pharma Group International | 10.94B |
| GenFleet Therapeutics (Shanghai) | 10.32B |
| Suzhou Ribo Life Science | 8.63B |
| HBM Holdings | 8.56B |
| Nanjing Leads Biolabs | 8.06B |
| Shaanxi Micot Pharmaceutical Technology | 7.96B |